We are live on ! Find out more
CC

Callan Capital Portfolio holdings

AUM $1.35B
1-Year Est. Return 8.35%
This Fund
S&P 500
This Quarter Est. Return
+4.96%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$904M
AUM Growth
+$40.3M
Cap. Flow
-$112K
Cap. Flow %
-0.01%
Top 10 Hldgs %
51.47%
Holding
194
New
10
Increased
69
Reduced
70
Closed
10

Top Buys

Rank Stock Value
1
FNDX icon
Schwab Fundamental US Large Company Index ETF
FNDX
+$13.7M
2
FNDF icon
Schwab Fundamental International Large Company Index ETF
FNDF
+$9.31M
3
AVUV icon
Avantis US Small Cap Value ETF
AVUV
+$5.28M
4
VTEB icon
Vanguard Tax-Exempt Bond Index Fund
VTEB
+$4.63M
5
FNDE icon
Schwab Fundamental Emerging Markets Large Company Index ETF
FNDE
+$4.39M

Top Sells

Rank Stock Value
1
GSIE icon
Goldman Sachs ActiveBeta International Equity ETF
GSIE
+$12.3M
2
GSLC icon
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
+$8.15M
3
SCHB icon
Schwab US Broad Market ETF
SCHB
+$3.99M
4
AVUS icon
Avantis US Equity ETF
AVUS
+$3.64M
5
INTF icon
iShares International Equity Factor ETF
INTF
+$2.93M

Sector Composition

Rank Sector Weight
1 Miscellaneous 90.87%
2 Technology 4.06%
3 Healthcare 1.11%
4 Financials 1.02%
5 Consumer Discretionary 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSTX
176
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$128K 0.01%
72,559
+4,552
+7% +$11.6K
CDTX
177
DELISTED
Cidara Therapeutics
CDTX
$117K 0.01%
5,173
– –
ALLO icon
178
Allogene Therapeutics
ALLO
$698M
$95.5K 0.01%
19,224
– –
EQ icon
179
Equillium
EQ
$152M
$77.8K 0.01%
103,688
– –
INFI
180
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$33.4K ﹤0.01%
158,500
– –
SRXH
181
SRX Global
SRXH
$34.7M
$30.1K ﹤0.01%
73
+51
+232% +$35.5K
CRDF icon
182
Cardiff Oncology
CRDF
$73.1M
$20K ﹤0.01%
13,587
– –
EFTR
183
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$16.6K ﹤0.01%
800
– –
BND icon
184
Vanguard Total Bond Market
BND
$161B
– –
-9,493
Closed -$701K
C icon
185
Citigroup
C
$223B
– –
-5,971
Closed -$280K
CMF icon
186
iShares California Muni Bond ETF
CMF
$4.62B
– –
-5,459
Closed -$313K
CVX icon
187
Chevron
CVX
$396B
– –
-1,888
Closed -$308K
ET icon
188
Energy Transfer Partners
ET
$73.4B
– –
-11,246
Closed -$140K
GM icon
189
General Motors
GM
$75.7B
– –
-7,216
Closed -$265K
BINI
190
DELISTED
Bollinger Innovations
BINI
– –
0
– -$2.63K
NKE icon
191
Nike
NKE
$58.7B
– –
-2,693
Closed -$330K
OXY icon
192
Occidental Petroleum
OXY
$59.1B
– –
-7,106
Closed -$444K
WFC icon
193
Wells Fargo
WFC
$262B
– –
-8,884
Closed -$332K
NXGN
194
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-104,307
Closed -$1.82M
4 5 6 7
8

Similar funds

MBA
Maple-Brown Abbott Barangaroo, Australia $1.47B AUM 27.26% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
AP
Adero Partners Pleasanton, California $1.53B AUM 5.52% 1-Year Est. Return
MW
Marcum Wealth Cleveland, Ohio $1.16B AUM 6.7% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
PAME
Parvus Asset Management Europe London, United Kingdom $1.67B AUM

Callan Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Callan Capital held 194 positions worth $904M, up 4.7% from $864M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Callan Capital's Q2 2023 filing shows 10 new, 69 increased, 70 reduced and 10 closed positions. Its largest new stake was iShares Russell 2000 ETF: 4,571 shares worth $856K. The largest sale was Goldman Sachs ActiveBeta International Equity ETF, an estimated $12.3M.

By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, up from 91% a quarter earlier, followed by Technology and Healthcare.

  • Callan Capital's largest Q2 2023 buy was iShares Russell 2000 ETF: 4,571 shares worth $856K.
  • Callan Capital added most to Schwab Fundamental US Large Company Index ETF in Q2 2023, an estimated $13.7M increase.
  • Callan Capital's biggest Q2 2023 reduction was Goldman Sachs ActiveBeta International Equity ETF, cutting an estimated $12.3M.
  • Callan Capital fully exited NextGen Healthcare, Inc. Common Stock in Q2 2023, selling an estimated $1.82M.
  • Callan Capital's ten largest holdings make up 51% of its $904M portfolio in Q2 2023.
  • Callan Capital opened 10 new positions and closed 10 in Q2 2023.
  • Callan Capital's portfolio value rose 4.7% quarter-over-quarter to $904M.

Based on Callan Capital's 13F filing for Q2 2023, filed 4 Aug 2023.